Abstract 4520: Using SEREX approach to screen and identify the tumor-associated antigens in non-small cell lung cancer

Abstract

Abstract Background: Lung cancer is the most common cause of cancer-related deaths worldwide and approximately 85% of lung cancer cases are non-small-cell lung cancer (NSCLC). The average survival and 5-year survival rates of NSCLC patients still remain poor. Autoantibodies against tumor-associated antigens (TAAs) have been shown to be relevant tumor markers. There is an urgent need to better understand the mechanism and to identify useful biomarkers for early immunodiagnosis of NSCLC. Materials and methods: Serological analysis of recombinant tumor cDNA expression libraries (SEREX) was applied to screen the lung cancer tumor-associated antigens (TAAs) with sera from lung cancer patients. Oncomine online database was used to analyze multiple microarray datasets and to identify potential genes in NSCLC progression. Autoantibody responses to TAAs were evaluated by enzyme-linked immunosorbent assay (ELISA) in sera from 196 patients with NSCLC and 196 normal controls. Result: Seventy positive clones had been screened by SEREX approach and 35 genes with known biological function were further identified by mass spectrometry analysis. Ten out of 35 genes were determined to be tested the corresponding autoantibodies since they were consistently over-expressed in NSCLC tissue in three mRNA arrays. The results of ELISA show that the level and positive frequency of the autoantibodies to TOP2A,ACTR3, RPS6KA5 and PSIP1 in sera from NSCLC patients were significantly higher than that in normal control (Ρ<0.05). The sensitivity of the four autoantibodies for diagnosis of NSCLC ranged from 17.4% to 32.1% with the specificity of 90%. The area under curve(AUC)of TOP2A,ACTR3, RPS6KA5 and PSIP1 was 0.758, 0.787, 0.707 and 0.668, respectively. The sensitivity of the panel of this four TAAs was 47.2% and the specificity was 81.5%. Conclusions: TOP2A, ACTR3, PSIP1, RPS6KA5 were tumor-associated antigens and their autoantibodies might be potential biomarkers for immunodiagnosis of NSCLC. Citation Format: Lu Pei, Tingting Wang, Peng Wang, Hongchun Liu, Songyun Ouyang, Jianying Zhang, Liping Dai. Using SEREX approach to screen and identify the tumor-associated antigens in non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4520.